Dr. Laura Spring, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 333
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Massachusetts Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
MA license 256404
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Cooley Dickinson Hospital Inc,the Northampton, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
- The General Hospital Corporation (1,267 clinicians)
- Mass General Brigham Medical Group Western Massachusetts Inc (291 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 333
- Services billed
- 1,027
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 247 | 94 |
| Established patient office or other outpatient visit, 30-39 minutes | 216 | 181 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Boston, MA | 110 |
| Exemestane | 25 |
| Anastrozole Other prescribers in Boston, MA | 21 |
| Ibrance (palbociclib) | 21 |
| Tamoxifen Citrate Other prescribers in Boston, MA | 14 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 12 |
| Alendronate Sodium Other prescribers in Boston, MA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 22 payments worth $17,927 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $10,435 |
|---|---|
| Daiichi Sankyo Inc. | $2,620 |
| Gilead Sciences, Inc. | $2,330 |
| Novartis Pharmaceuticals Corporation | $2,271 |
| Stemline Therapeutics Inc. | $196 |
| Pfizer Inc. | $73.88 |
| Consulting Fee | $17,044 |
|---|---|
| Food and Beverage | $883 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Consulting Fee DATROWAY · Oncology | $2,740 |
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $2,569 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee DATROWAY · Oncology | $2,460 |
| Gilead Sciences, Inc. Dec 18, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4283678;VEM US;11099519 | $2,180 |
| Novartis Pharmaceuticals Corporation May 31, 2025 | Consulting Fee KISQALI · Oncology | $2,100 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| AstraZeneca Pharmaceuticals LP Mar 7, 2025 | Consulting Fee | $820 |
| AstraZeneca Pharmaceuticals LP Sep 2, 2025 | Consulting Fee | $615 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Consulting Fee | $410 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 18, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4283678;VEM US;11099519 | $2,180 |
| AstraZeneca Pharmaceuticals LP Dec 1, 2025 | Consulting Fee | $410 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee DATROWAY · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Sep 2, 2025 | Consulting Fee | $615 |
| Novartis Pharmaceuticals Corporation May 31, 2025 | Consulting Fee KISQALI · Oncology | $2,100 |
| Daiichi Sankyo Inc. May 14, 2025 | Consulting Fee DATROWAY · ONCOLOGY | $2,569 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Consulting Fee DATROWAY · Oncology | $2,740 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Consulting Fee | $410 |
| AstraZeneca Pharmaceuticals LP Mar 7, 2025 | Consulting Fee | $820 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
| AstraZeneca Pharmaceuticals LP Feb 6, 2025 | Consulting Fee LYNPARZA · Oncology | $1,370 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $2,849,414 in research payments for these studies, mostly to the institutions running them.
- A phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer (NeoSTAR)
Merck Sharp & Dohme LLC - A phase 2 study of response-guided neoadjuvant Sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer
Gilead Sciences, Inc. - P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, Triple Negative Breast Cancer
Merck Sharp & Dohme LLC - A phase 1B2 openlabel study of disitamab vedotin in combination with other anticancer therapies in solid tumors
Pfizer Inc. - STUDY NAME#HR P-RAD# A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Low or High Dose RADiation in Node-Positive, HR Breast Cancer
Merck Sharp & Dohme LLC - A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Posi…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.